Published July 18, 2024 | Version v1

Heavy-atom-free π-twisted photosensitizers for fluorescence bioimaging and photodynamic therapy

Description

As the field of preclinical research on photosensitizers (PSs) for anticancer photodynamic therapy (PDT) continues to expand, a focused effort is underway to develop agents with innovative molecular structures that offer enhanced targeting, selectivity, activation, and imaging capabilities. In this context, we introduce two new heavy-atom-free PSs, DBXI and DBAI, characterized by a twisted π-conjugation framework. This innovative approach enhances the spin–orbit coupling (SOC) between the singlet excited state (S1) and the triplet state (T1), resulting in improved and efficient intersystem crossing (ISC). Both PSs are highly effective in producing reactive oxygen species (ROS), including singlet oxygen and/or superoxide species. Additionally, they also demonstrate remarkably strong fluorescence emission. Indeed, in addition to providing exceptional photocytotoxicity, this emissive feature, generally lacking in other reported structures, allows for the precise monitoring of the PSs’ distribution within specific cellular organelles even at nanomolar concentrations. These findings underscore the dual functionality of these PSs, serving as both fluorescent imaging probes and light-activated therapeutic agents, emphasizing their potential as versatile and multifunctional tools in the field of PDT.

Files

JMCB.zip

Files (158.5 MB)

Name Size Download all
md5:1ae94515e80ff42bd26815bb88aba95d
158.5 MB Preview Download

Additional details

Funding

National Science Centre
Molecular insights into hypoxic tumors – for development of targeted cancer therapeutics 2022/47/P/NZ5/01156